To include your compound in the COVID-19 Resource Center, submit it here.

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin
Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or

Read the full 311 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers